Antioxidants and CVD in diabetes: Where do we stand now?

被引：27
|
作者：
Yim S. [1 ]
Malhotra A. [1 ]
Veves A. [1 ]
机构：
[1] Microcirculation Laboratory, Palmer 321A, Beth Israel Deaconess Medical Center, Boston, MA 02215, One Deaconess Road
来源：
Current Diabetes Reports | 2007年 / 7卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Endothelial Dysfunction; Physiol Heart Circ; Polyol Pathway; Benfotiamine; Smooth Muscle Cell Growth;
D O I：
10.1007/s11892-007-0003-9
中图分类号：
学科分类号：
摘要：
Diabetes is an oxidative stress disorder as a result of both hyperglycemia and increased levels of free fatty acids. Oxidative stress has been implicated in the pathogenesis of diabetes-related complications, and treatment with antioxidants seemed to be a promising therapeutic option. Although animal studies and preliminary human studies were initially encouraging, subsequent human studies have failed to show a clear benefit of antioxidants, whereas some studies have even suggested that they can be potentially harmful. Therefore, treatment with antioxidants cannot be currently recommended as a therapeutic option. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：8 / 13
页数：5
相关论文
共 50 条
  • [21] An insight into iTRAQ: where do we stand now?
    Caroline Evans
    Josselin Noirel
    Saw Yen Ow
    Malinda Salim
    Ana G. Pereira-Medrano
    Narciso Couto
    Jagroop Pandhal
    Duncan Smith
    Trong Khoa Pham
    Esther Karunakaran
    Xin Zou
    Catherine A. Biggs
    Phillip C. Wright
    Analytical and Bioanalytical Chemistry, 2012, 404 : 1011 - 1027
  • [22] Biologics in vasculitides: Where do we stand, where do we go from now?
    Pazzola, Giulia
    Muratore, Francesco
    Pipitone, Nicolo
    Salvarani, Carlo
    PRESSE MEDICALE, 2015, 44 (06): : E231 - E239
  • [23] Low Dose CT: Where Do We Stand Now?
    Leng, Shuai
    Chen, G.
    Stayman, J.
    McCollough, C.
    Pickhardt, P.
    MEDICAL PHYSICS, 2017, 44 (06) : 3248 - 3249
  • [24] COMMON FUND DEBATE - WHERE DO WE STAND NOW
    SINGER, HW
    ROUND TABLE, 1978, (271): : 229 - 235
  • [25] Accelerated Approval of Aducanumab: Where Do We Stand Now?
    Barenholtz Levy, Hedva
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (06) : 736 - 739
  • [26] Genetic Architecture of Depression: Where Do We Stand Now?
    Unal-Aydin, Pinar
    Aydin, Orkun
    Arslan, Ayla
    MAJOR DEPRESSIVE DISORDER: RETHINKING AND UNDERSTANDING RECENT DISCOVERIES, 2021, 1305 : 203 - 230
  • [27] WHERE WE NOW STAND
    LUMSDEN, KG
    JOURNAL OF ECONOMIC EDUCATION, 1969, 1 (01): : 12 - 19
  • [28] ASPIRIN FOR THE PREVENTION OF PREECLAMPSIA - WHERE DO WE STAND NOW
    YLIKORKALA, O
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1995, 74 (06) : 407 - 409
  • [29] Adolescent Fertility Preservation: Where Do We Stand Now
    Alur-Gupta, Snigdha
    Vu, Michelle
    Vitek, Wendy
    SEMINARS IN REPRODUCTIVE MEDICINE, 2022, 40 (01/02) : 69 - 78
  • [30] Bladder Pain Syndrome: Where Do We Stand Now?
    Chang Kit L.
    Current Bladder Dysfunction Reports, 2014, 9 (1) : 32 - 40
12345